Foundation Fighting Blindness: Atsena's LCA1 Gene Therapy Licensed by Nippon Shinyaku for Markets in US and Japan
November 14, 2024
November 14, 2024
COLUMBIA, Maryland, Nov. 14 -- The Foundation Fighting Blindness issued the following news:
* * *
The companies are planning a Phase 3 clinical trial for the promising gene therapy.
* * *
Nippon Shinyaku, a pharmaceutical company based in Kyoto, Japan, and Atsena Therapeutics, a developer of gene therapies for retinal diseases in Durham, North Carolina, have entered into a license agreement for the commercialization of ATSN-101, an emerging gen . . .
* * *
The companies are planning a Phase 3 clinical trial for the promising gene therapy.
* * *
Nippon Shinyaku, a pharmaceutical company based in Kyoto, Japan, and Atsena Therapeutics, a developer of gene therapies for retinal diseases in Durham, North Carolina, have entered into a license agreement for the commercialization of ATSN-101, an emerging gen . . .